U.S. Markets close in 17 mins.

Regulus Therapeutics Inc. (RGLS)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
0.99+0.04 (+4.31%)
As of 3:42PM EDT. Market open.
People also watch
Full screen
Previous Close0.95
Bid0.99 x 200
Ask0.99 x 100
Day's Range0.94 - 1.00
52 Week Range0.86 - 5.74
Avg. Volume984,989
Market Cap52.65M
PE Ratio (TTM)-0.65
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • SmarterAnalyst9 days ago

    Chardan Capital Slashed Price Target on Regulus Therapeutics Inc (RGLS) Following Program Discontinuations

    Yesterday, Regulus Therapeutics Inc (NASDAQ:RGLS) disclosed unpleasant updates regarding the company’s pipeline. The drug maker announced three program discontinuations, which include drugs: RG-101, a miR-122 inhibitor for the treatment of hepatitis C, RG-125, a miR-103/107 inhibitor for the treatment of non-alcoholic steatohepatitis, and RGLS5040, a miR-27 inhibitor for the treatment for cholestatic disorders. In the wake of the clinical updates, Chardan analyst Madhu Kumar slashed his price target to $5.00 (from $2.50), while reiterating a Buy rating on the stock. To the company’s credit, the analyst points out that the company's lead drug RG-012, a miR-21 inhibitor for the treatment of Alport syndrome, is still on the run and has a “favorable risk-benefit profile." Kumar reminds “The phase II HERA trial is expected to provide renal biopsy data by year end-2017 and interim efficacy data by mid-2018,” and highlights the drug maker’s future is strongly linked to RG-012 performance.

  • TheStreet.com9 days ago

    Regulus, AstraZeneca Cut Ties on Liver Disease Treatment, Shares Dip

    After Regulus dropped two of its drug programs, AstraZeneca ditched the duo's drug partnership, too.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of RGLS earnings conference call or presentation 4-May-17 9:00pm GMT

    Q1 2017 Regulus Therapeutics Inc Earnings Call